License-in (originals)
Women’s Health
| Territory: | European Union (EU), Russia and
Commonwealth of Independent States (CIS), China, Latin-America
|
| We are
searching for: | clinical phase projects with at least an efficacy signal,
registered or marketed products |
| We
offer: | co-development and co-financing, registration, participation in
P&R approval, sales and marketing |
Central Nervous System
| Territory: | European Union (EU), Russia and Commonwealth of Independent States
(CIS), China |
| We are
searching for: | preclinical and early clinical phase projects (Ph1, Ph2a) in
dementia, autism and obesity, registered or marketed
products in all CNS indications |
| We
offer: | acquisition of early
developments, co-development and co-financing, registration, participation in
P&R approval, sales and marketing |
Other therapy areas
(Cardiovascular, Rheumatology, Respiratory,
Anti-infectives), OTC products
| Territory: | Central and Eastern Europe (CEE), Russia and Commonwealth of Independent States
(CIS), China |
| We are
searching for: | late-stage clinical phase projects, registered or marketed
products |
| We
offer: | co-financing, registration, participation in P&R approval, sales and marketing |
Joint development
We offer early Research and
Development collaborations in dementia, migraine prophylaxis, autism and obesity
and participation in the design and running of clinical trials in strategically
selected areas within the Central Nervous System and Gynecology.
Technology transfer & manufacturing
With the ability to manufacture a
broad range of finished dosage forms in state of the art EMA and FDA approved
facilities in Hungary, Poland, Romania, Russia and Germany Richter is open to
discuss manufacturing opportunities of innovative license-in projects. Richter
is also actively searching for contract manufacturing opportunities for his
state-of-the-art manufacturing facilities with a special emphasis on contract
development and manufacturing of steroid APIs and finished dosage forms, and
contract manufacturing of microbial and mammalian-cell based biotechnology
compounds.
